Advertisement

Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m2 or more

      Highlights

      • 1-
        This is a report of a pilot trial designed to test the feasibility and impact of using phentermine/topiramate extended release (phen/top) pre and postoperatively in patients with super obesity undergoing sleeve gastrectomy (LSG).
      • 2-
        The phen/top treatment group lost over 2 times as much weight (28.1±12.8 kg vs 12.3±12.5 kg) during preoperative treatment as compared to controls.
      • 3-
        At 2 years, there was an excess weight loss percent difference of -18.2% (95% CI, -32.1, -4.4) that favored the phen/top treatment group.
      • 4-
        In patients with super obesity, a higher proportion treated with phen/top plus LSG treatment compared to LSG alone achieved a BMI <40 kg/m2 at 2 years of treatment.

      Abstract

      Background

      Super obesity (body mass index [BMI] ≥50 kg/m2) treatment can be complicated and high risk.

      Objectives

      We studied whether the pre and postoperative use of phentermine and topiramate (phen/top) combined with laparoscopic sleeve gastrectomy (LSG) in super obesity increases the odds of achieving a BMI <40 at 2 years postoperatively.

      Setting

      Academic medical center in Winston Salem, North Carolina.

      Methods

      We recruited patients between 2014 and 2016 who had a BMI ≥50 and planned to undergo LSG (n = 25) to participate in an open-label trial. Participants took phen/top (7.5/46–15/92 mg/d) for at least 3 months preoperatively and 2 years postoperatively. We compared weight loss, BMI changes, and odds for achieving BMI <40 for phen/top + LSG to historical controls. Controls had an initial BMI ≥50 and underwent LSG, without phen/top, at our center during the same timeframe (n = 40).

      Results

      Of the 25 participants recruited, 13 completed LSG. Phen/top participants had a baseline BMI of 61.2 ± 7.1 kg/m2 compared with 57.0 ± 5.6 kg/m2 for control participants. Percent initial weight loss was –39.3% (phen/top + LSG) versus –31.4% (control) at 12 months, P = .018; by 24 months, phen/top + LSG had an 11.2% greater initial weight loss, P = .007. At 24 months, the mean BMI was 33.8 kg/m2 for phen/top versus 42 kg/m2 for controls. The odds ratio for achieving a BMI <40 at 2 years with phen/top + LSG versus LSG alone was 4.1 (95% confidence interval, 0.8–21).

      Conclusions

      Compared with LSG alone, phen/top combined with LSG may help patients with a BMI >50 achieve greater weight loss and reach a BMI <40. Long-term, controlled trials are needed to follow up these results.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery for Obesity and Related Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sturm R.
        • Hattori A.
        Morbid obesity rates continue to rise rapidly in the United States.
        Int J Obes. 2013; 37: 889-891
        • Nguyen N.
        • Champion J.K.
        • Ponce J.
        • et al.
        A review of unmet needs in obesity management.
        Obes Surg. 2012; 22: 956-966
        • Alexandrou A.
        • Felekouras E.
        • Giannopoulos A.
        • Tsigris C.
        • Diamantis T.
        What is the actual fate of super-morbid-obese patients who undergo laparoscopic sleeve gastrectomy as the first step of a two-stage weight-reduction operative strategy?.
        Obes Surg. 2012; 22: 1623-1628
        • Brethauer S.A.
        • Hammel J.P.
        • Schauer P.R.
        Systematic review of sleeve gastrectomy as staging and primary bariatric procedure.
        Surg Obes Relat Dis. 2009; 5: 469-475
        • Landreneau J.P.
        • Strong A.T.
        • Rodriguez J.H.
        • et al.
        Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass.
        Obes Surg. 2018; 28: 3843-3850
        • Fujioka K.
        Safety and tolerability of medications approved for chronic weight management.
        Obesity. 2015; 23: S7-S11
      1. American Society for Metabolic and Bariatric Surgery [homepage on the Internet]. Gainesville: The Society; c2019 [published June 2018; accessed 2019 Jan 10]. Estimate of Bariatric Surgery Numbers, 2011–2017 [1 screen].
        (Available from:)
        • Bettencourt-Silva R.
        • Neves J.S.
        • Pedro J.
        • et al.
        Comparative effectiveness of different bariatric procedures in super morbid obesity.
        Obes Surg. 2019; 29: 281-291
        • Jain D.
        • Sill A.
        • Averbach A.
        Do patients with higher baseline BMI have improved weight loss with Roux-en-Y gastric bypass versus sleeve gastrectomy?.
        Surg Obes Relat Dis. 2018; 14: 1304-1309
        • Arman G.A.
        • Himpens J.
        • Dhaenens J.
        • Ballet T.
        • Vilallonga R.
        • Leman G.
        Long-term (11+years) outcomes in weight, patient satisfaction, comorbidities, and gastroesophageal reflux treatment after laparoscopic sleeve gastrectomy.
        Surg Obes Relat Dis. 2016; 12: 1778-1786
        • Noel P.
        • Nedelcu M.
        • Eddbali I.
        • Manos T.
        • Gagner M.
        What are the long-term results 8 years after sleeve gastrectomy?.
        Surg Obes Relat Dis. 2017; 13: 1110-1115